AmInvest Research Reports

Apex Healthcare - Record FY23 Revenue With Special Dividend of 20 Sen

AmInvest
Publish date: Thu, 22 Feb 2024, 10:05 AM
AmInvest
0 8,750
An official blog in I3investor to publish research reports provided by AmInvest research team.

All materials published here are prepared by AmInvest. For latest offers on AmInvest trading products and news, please refer to: https://www.aminvest.com/eng/Pages/home.aspx

Tel: +603 2036 1800 / +603 2032 2888
Fax: +603 2031 5210
Email: enquiries@aminvest.com

Office Hours
Monday to Thursday: 8:45am – 5:45pm
Friday: 8:45am – 5:00pm
(GMT +08:00 Malaysia)

Investment Highlights

  • We reiterate HOLD on Apex Healthcare (Apex) with an unchanged ex-dividend fair value (FV) of RM2.64/share (ex- date on 15 May 2024), based on a FY24F target PE of 20x, at parity to its 5-year average. No ESG-related adjustments based on our neutral 3-star rating.
  • We maintain FY24F-25F earnings as Apex’s FY23 core net profit of RM93mil generally came in within expectations, coming in 1% below our forecast and 3% of street’s. In our core profit calculation, we excluded the revised one-off gain of RM322mil from a partial divestment of the group’s orthopaedic business, Straits Apex (SA).
  • In addition, we introduce FY26F earnings with a 8.5% YoY growth, underpinned by an ageing population, public health education advancement and continuously expanding healthcare expenditure.
  • The group declared a final dividend of 2.5 sen/share and special dividend of 20 sen/share in 4QFY23, bringing FY23 total dividend to 25 sen/share (implying a payout of 193%). As a comparison, our FY23F DPS of 5.5 sen/share excludes Apex’s partial distribution of the cash proceeds received from 40%-owned Strait Apex Group (SAG). Hence, we maintain FY24F-25F DPS and introduce FY26F dividend of 6.5 sen.
  • On a YoY basis, Apex’s 4QFY23 core earnings deteriorated by 40% despite a 9% revenue growth. This was primarily attributed to: (a) lower contribution from 16%-owned SA as a result of reduced equity stake and higher amortisation expenses as well as (b) higher tax expenses.
  • On a QoQ basis, Apex’s 4QFY23 core earnings decreased by 21% despite a flattish 2% improvement in revenue. The weaker earnings were mainly impacted by (a) lower gross profit margin of 21.5% (-2.1%-point QoQ) as a result of lower revenue share from higher-margin manufacturing segment, (b) lower contribution from SA as a result of higher amortisation costs, and (c) higher tax expenses.
  • Going into FY24F, we expect Apex to register a 7% revenue growth albeit a flattish earnings growth following the lower effective equity stake in SA from 40% to 16% since May 2023. In addition, Apex plans to submit applications to relevant authorities this year for the expansion of warehouses and liquid production facilities in a newly acquired 20.7-acre land. Nevertheless, the earnings contribution from this initiative may materialise beyond 2025.
  • The stock currently trades at a fairly-valued FY24F PE of 21x, 5% premium to its 5-year average of 20x. Also, Apex offers a slight dividend yield of 1.8%.

Source: AmInvest Research - 22 Feb 2024

Related Stocks
Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment